Mergers and Acqusitions news from FierceBiotech
NewsAnalysts predict more M&A as capital shrinks
A shortage of new money is likely to drive more and more life sciences companies into mergers and acquisitions, say some of the Read more...
Lilly pays $35M to land TransPharma pact
Eli Lilly is forking over a $35 million upfront payment to nail down the worldwide licensing rights to TransPharma Medical's ViaDerm-hPTH osteoporosis product and a non-exclusive license to its Read more...
Daiichi Sankyo acquires Ranbaxy in $4.6B deal
Ranbaxy's drive to become a research-based drug developer and major manufacturer has led it straight into the Read more...
Ipsen inks a string of deals in expansion effort
France's Ipsen is buying out Tercica in a $404 million deal, one of three new pacts designed to Read more...
Takeda gains RNAi tech with $1B Alnylam deal
Takeda's quest to expand in the U.S. market--and off-set expiring patents on big drugs--continues. The Japanese company announced today a $1 billion alliance with RNAi company Alnylam. The deal Read more...
Biotech M&A has yet to reach its peak
In analyzing the PowerShares Dynamic Biotech & Genome ETF, a fund made up of primarily small- and medium-cap biotech stocks, Seeking Alpha notes that Big Pharma's appetite for biotech Read more...
GSK buys Sirtris for $720M
GlaxoSmithKline is acquiring Cambridge, MA-based Sirtris Pharmaceuticals for $720 million. GSK will pay $22.50 per share for the company--an 84 percent premium to Sirtris's closing price Tuesday. Read more...
Novartis CEO: Deals possible in diagnostics, vaccines
Novartis AG CEO Daniel Vasella (photo) concedes that his company is going through a rough stage, but insists that a Read more...
Pfizer snaps up Serenex in buyout
Pfizer has beefed up its prospects in the cancer arena with today's buyout of Durham, NC-based Serenex. The biotech Read more...
Antisoma scouts for new therapies to add to pipeline
Antisoma is sending out signals that it's looking for new acquisitions to add to its pipeline. "With a strong balance sheet, we are well placed to invest in and add value to our current pipeline and Read more...
| Press ReleasesPRESS RELEASE: Schering-Plough Corporation Completes $14.43 Billion Acquisition of Organon Schering-Plough Corporation Completes $14.43 Billion Acquisition of Organon KENILWORTH, N.J., Nov. 19 /PRNewswire-FirstCall/ -- Schering-Plough Corporation today announced that it has completed the Read more... PRESS RELEASE: Pfizer to Acquire Coley Pharmaceutical Group Pfizer to Acquire Coley Pharmaceutical Group Acquisition Will Expand Pfizer's Investment in Vaccines, Broaden Scope of Research in a Number of Key Therapeutic Areas NEW YORK & WELLESLEY, Mass. Read more... PRESS RELEASE: Aspreva Pharmaceuticals Corporation to be Acquired by Galenica For $915 Million Aspreva Pharmaceuticals Corporation to be Acquired by Galenica For $915 Million VICTORIA, Oct. 17 - Aspreva Pharmaceuticals Corporation today announced that it has entered into a combination Read more... PRESS RELEASE: Bristol-Myers Squibb to Buy Partner Adnexus Therapeutics for $430 Million Bristol-Myers Squibb to Buy Partner Adnexus Therapeutics for $430 Million PRINCETON, N.J. and WALTHAM, Mass., Sept. 24 -- Bristol-Myers Squibb Company and Adnexus(TM) Therapeutics announced today Read more... |
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets